Calcutta High Court: The present case concerns allegations of patent infringement and breach of confidentiality arising from the proposed manufacture of 4-Aminodiphenylamine (4-ADPA) by the respondent Company, allegedly using processes patented by the petitioner Company. The Single Judge Bench of Ravi Krishan Kapur, J. held that the petitioner had established a strong prima facie case of patent infringement and breach of confidentiality. Finding the defendants’ conduct evasive and their explanations unconvincing, the Court granted interim relief in favour of NOCIL.
Background
The dispute arose when the petitioner Company (NOCIL) discovered that its former employee (Respondent 2) had joined respondent Company (Finorchem) after retiring from NOCIL and was allegedly assisting the company in establishing its 4-ADPA manufacturing operations. In approximately 2012, NOCIL developed this novel industrial process for manufacturing 4-Aminodiphenylamine, commonly known as 4-ADPA.
The petitioner Company is one of India’s leading manufacturers of rubber chemicals and has consistently invested in research and development to develop innovative chemical manufacturing processes. 4-ADPA is used as an antioxidant in rubber and polymer applications and as an intermediate in the manufacture of other antioxidants. Around 2012, NOCIL developed an innovative process for manufacturing 4-ADPA, incorporating improvements in manufacturing efficiency and technical characteristics. It subsequently obtained 3 Indian patents, along with corresponding patent registrations in the United States. These patents covered different aspects of the manufacturing process and granted NOCIL exclusive rights over the patented inventions.
Respondent 2 had joined NOCIL in 1987 as a production supervisor and retired on 30 September 2020 as Deputy General Manager — Process Technology. During his employment, he was transferred to NOCIL’s Dahej manufacturing facility, where he became involved in the development and implementation of proprietary manufacturing processes relating to 4-ADPA. His position and responsibilities provided him access to confidential technical information, manufacturing procedures, research findings and trade secrets concerning the patented processes. Importantly, on 11 May 2012, Respondent 2 executed a non-disclosure agreement (NDA) with NOCIL. The agreement specifically referred to the 4-ADPA project and recognised that the employee was part of a technical working group involved in developing unique manufacturing methods through laboratory and pilot-plant experiments before commercialisation.
The petitioner subsequently discovered an Environmental Impact and Risk Assessment (EIRA) Report submitted by Finorchem Ltd. for its proposed 4-ADPA manufacturing facility. Upon examining the report and conducting further enquiries, NOCIL found that its former employee had joined Finorchem and was allegedly assisting it in establishing its manufacturing operations. NOCIL noticed substantial similarities between Finorchem’s EIRA Report and its own earlier report, raising suspicions that Finorchem had obtained confidential technical information through Respondent 2 and intended to manufacture 4-ADPA using processes substantially similar to NOCIL’s patented inventions.
Following correspondence between the parties, NOCIL initiated proceedings alleging patent infringement, breach of contractual confidentiality obligations and misappropriation of trade secrets. The dispute intensified when Finorchem filed a patent application relating to a 4-ADPA manufacturing process on 19 April 2024. By an order dated 26 November 2025, the Court directed Finorchem to disclose evidence of the manufacturing process it proposed to employ. Finorchem subsequently sought amendments to its patent application on 6 February 2026. NOCIL alleged that these repeated changes were intended to disguise the similarities between the competing processes and avoid infringement liability. It further contended that Respondent 2 had breached his NDA and that Finorchem had knowingly induced and benefited from the breach.
Finorchem denied infringement and maintained that its proposed manufacturing process was materially different from NOCIL’s patented processes. It also challenged the validity of NOCIL’s patents, arguing that their registration did not establish their validity. Respondent 2 denied possessing or disclosing confidential information and contended that he had neither directly participated in developing the patented inventions nor been named as their inventor. NOCIL consequently sought interim relief restraining the respondents from infringing its process patents and misappropriating or misusing its confidential information and trade secrets.
Decision and Analysis
The Court examined the legal position concerning the validity of granted patents. Referring to Sections 12 and 13(4), Patents Act, 1970, it clarified that registration does not conclusively establish patent validity and that granted patents remain open to challenge on recognised legal grounds. Unlike Section 31, Trade Marks Act, 1999, the Patents Act does not provide an equivalent statutory presumption of validity as supported in the case of Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries, (1979) 2 SCC 511. Nevertheless, the Court observed that a patent granted after examination deserves due consideration at the interim stage and cannot be disregarded outrightly.
The Court further emphasised that the age, established nature and commercial exploitation of a patent are relevant considerations while assessing an interim injunction. NOCIL’s patents had undergone extensive examination in India and other jurisdictions, had been commercially exploited for years and had enjoyed uninterrupted exclusive use. Although these circumstances did not create a presumption of validity, they warranted due weight at the prima facie stage.
The Court also considered Sections 107 and 64, Patents Act, under which a defendant may raise any ground available for revocation of a patent as a defence to infringement proceedings. However, merely questioning patent validity or filing a counterclaim does not automatically defeat an application for an injunction. The defendant must demonstrate a credible and sustainable challenge supported by genuine legal and factual grounds, rather than a fanciful or speculative objection. Applying this principle, the Court found that Finorchem had failed to establish a sufficiently credible challenge to NOCIL’s patents.
The Court noted a striking similarity between the EIRA Reports submitted by the parties. The Court found that Finorchem’s report substantially reproduced NOCIL’s earlier report. The explanation that both reports had been prepared by the same agency was considered inadequate. The Court reasoned that such extensive similarities could not reasonably be explained unless the underlying manufacturing processes were substantially identical.
The Court also considered Finorchem’s failure to pursue appropriate statutory remedies to challenge NOCIL’s patents before proceeding with its proposed manufacturing activities. These remedies included pre-grant opposition under Section 25(1), post-grant opposition under Section 25(2), a declaration of non-infringement under Section 105 and revocation proceedings under Section 64. Referring to the principle of clearing the way, the Court observed that a prospective manufacturer intending to undertake activities potentially covered by an existing patent should take appropriate steps to resolve the patent dispute before commencing commercial operations. Finorchem’s failure to pursue these available remedies was considered a relevant factor while assessing its conduct and the balance of convenience.
The Court also expressed concern regarding Finorchem’s inconsistent disclosure of its proposed manufacturing process. It noted that the original EIRA Report disclosed a process substantially similar to NOCIL’s patented process, whereas subsequent patent application amendments introduced variations that were later abandoned or modified. These changes included alterations to the reactants, molar ratios and second hydrogenation stage. The Court considered the repeated alterations suspicious and observed that they appeared intended to create artificial distinctions between the competing processes and avoid infringement liability. On comparing the technical features of the processes, the Court identified several common steps, including the reaction of aniline with tetramethylammonium hydroxide, addition of nitrobenzene, use of continuous reactors, hydrogenation, catalyst filtration, separation of organic and aqueous phases, recycling of the aqueous base, dehydration, distillation and recovery of 4-ADPA.
In determining infringement, the Court applied the principle of pith and marrow, emphasising that the assessment must focus on the essential inventive features of the patented process rather than minor technical variations or differences in terminology. Superficial modifications would not avoid infringement where the essential elements and inventive characteristics remained substantially similar. The expert evidence submitted by NOCIL supporting the equivalence of the processes remained uncontroverted. The Court relying on the case of Raj Parkash v. Mangat Ram Chowdhry, 1977 SCC OnLine Del 33 considered the burden of proof under Section 104-A, Patents Act concerning the process used in manufacturing the product. It rejected Finorchem’s reliance on the cited prior-art references, observing that the relevant prior arts had already been considered and overcome in patent proceedings in India and the United States. It further held that separate prior-art documents could not be impermissibly combined through mosaicing to establish anticipation.
On confidentiality, the Court examined the NDA executed by Respondent 2 and found that it specifically covered the 4-ADPA project, clearly imposing an obligation to protect confidential technical information obtained during his employment. The Court referring to the case of Hi-Tech Systems & Services Ltd. v. Suprabhat Ray, 2015 SCC OnLine Cal 1192 observed that an employee or former employee cannot exploit an employer’s confidential information and trade secrets for personal benefit or to assist a competing enterprise. An organisation knowingly procuring or benefiting from such a breach may also be restrained. The Court rejected the argument that patent infringement and breach of confidentiality were mutually destructive claims. The court took reference from Zee Teleflims Ltd. v. Sundial Communications (P) Ltd. 2003 SCC OnLine Bom 344, and clarified that information may retain its confidential character even if certain individual elements are publicly available. Patent specifications do not necessarily disclose every item of confidential commercial or technical information associated with an invention.
The Court concluded that NOCIL had established a strong prima facie case through its existing patents, the substantial similarity between the competing processes, the similarities in the EIRA Reports and the evidence concerning the former employee’s access to confidential information. The balance of convenience also favoured NOCIL because Finorchem had not yet commenced commercial production. Consequently, restraining its proposed activities would cause comparatively less prejudice than allowing potentially infringing manufacturing operations to proceed.
The Court also noted that Finorchem had not yet commenced commercial production. Consequently, the balance of convenience favoured NOCIL, as allowing potentially infringing manufacturing operations to proceed could cause serious and irreparable commercial and competitive injury that monetary compensation might not adequately remedy.
Accordingly, the Court held that NOCIL had established a strong prima facie case, that the balance of convenience lay in its favour and that irreparable injury would be caused if interim protection was denied. It granted interim relief in favour of NOCIL in terms of prayers (a) and (b) of the Notice of Motion and disposed of the interim application.
[Nocil Ltd. v. Finorchem Ltd., 2026 SCC OnLine Cal 15454, decided on 7-10-2026]
Advocates who appeared in this case:
For the Plaintiff: Ranjan Bachawat, Senior Advocate, Nishad Nadherni, Shounak Mitra, Nisha Austine, Vaibhavi Pandey, Khushboo Jhunjhunwala, Arakadeep Kundu, Bhavesh Garodia, Rakshita Singh, Tiasha Gupta, Advocates
For the Respondent: S.N. Mookherjee, Rudraman Bhattacharyya, Senior Advocate, Sidhartha Das, Saptarshi Mukherjee, Akash Munshi, Yamini Mookherjee, Souvik Kundu, Sourojit Dasgupta, Satyaki Mukherjee, Amrita Panja Moulick, Advocates





0 replies